Gridelli, Cesare
Rossi, Antonio
Carbone, David P.
Guarize, Juliana
Karachaliou, Niki
Mok, Tony
Petrella, Francesco
Spaggiari, Lorenzo
Rosell, Rafael
Article History
First Online: 21 May 2015
Competing interests
: C.G. has received honoraria, speaker's fees, research funding and/or has served as an advisor to Eli Lilly, Roche, Novartis, Bristol-Meyers Squibb, Pfizer, and Boehringer Ingelheim. A.R. has received honoraria, speaker's fees and/or has served as an advisor to Eli Lilly, AstraZeneca and Boehringer Ingelheim. D.P.C. has been a paid consultant for Roche/Genentech, Pfizer, Novartis, BioDesix, Merck, EMD Serono, GlaxoSmithKline, Boehringer Ingelheim and Amgen. T.M. has received honoraria, speaker's fees, research funding and/or has served as an advisor to: AstraZeneca, Roche/Genentech, Eli Lilly, EMD Serono, Eisai, Bristol-Meyers Squibb, AVEO, Pfizer, Taiho, Boehringer Ingelheim, Novartis, GlaxoSmithKline Biologicals, Clovis Oncology, Amgen, Janssen and BioMarin Pharmaceuticals. J.G., N.K., F.P., L.S. and R.R. declare no competing interests.